Evidence map›Paper›PMID 39076203›Full record

ReviewReviews in cardiovascular medicine2022

Inclisiran: A New Pharmacological Approach for Hypercholesterolemia.

Stefania Angela Di Fusco, Aldo Pietro Maggioni, Chiara Bernelli, Francesco Perone, Vincenzo De Marzo, Edoardo Conte, Francesca Musella, Giuseppe Uccello, Leonardo De Luca, Domenico Gabrielli and 3 more

Abstract readReview
PubMed Full text at PMC Publisher
In one paragraph

Review in Reviews in cardiovascular medicine, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 16 papers.

0numbers the graph read from it
0cells of the map it votes in
16citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

16 citing papers in PubMed.

  1. Review
  2. Review
  3. Review
  4. Review
  5. Review
  6. Article
  7. Review
  8. Review
  9. Review
  10. Article
  11. Article
  12. Review
  13. Review
  14. Review
  15. Article
  16. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

13 authors.

Stefania Angela Di FuscoEmergency Department, Clinical and Rehabilitation Cardiology Unit, San Filippo Neri Hospital, ASL Roma 1, 00135 Rome, Italy.
Aldo Pietro MaggioniANMCO Research Center, Heart Care Foundation, 50121 Florence, Italy.
Chiara BernelliCardiology Department, Interventional Cardiology Unit, Ospedale Santa Corona, 17027 Pietra Ligure, Italy.
Francesco PeroneCardiac Rehabilitation Unit, Rehabilitation Clinic "Villa delle Magnolie", Castel Morrone, 81100 Caserta, Italy.
Vincenzo De MarzoCardioThoracic and Vascular Department, San Martino Policlinico Hospital, IRCCS for Oncology and Neurosciences, 16100 Genoa, Italy.
Edoardo ConteDepartment of Biomedical Sciences for Health, IRCCS Ospedale Galeazzi-Sant'Ambrogio, University of Milan, 20161 Milan, Italy.
Francesca MusellaDivision of Cardiology, Ospedale Santa Maria delle Grazie Pozzuoli, 80078 Napoli, Italy.
Giuseppe UccelloCardiovascula Department, Clinical and Interventional Cardiology Unit, Istituto Clinico Sant'Ambrogio, 20149 Milan, Italy.
Leonardo De LucaDipartimento Cardio-Toraco-Vascolare, U.O.C. Cardiologia, Azienda Ospedaliera San Camillo Forlanini, 00152 Roma, Italy.
Domenico GabrielliDipartimento Cardio-Toraco-Vascolare, U.O.C. Cardiologia, Azienda Ospedaliera San Camillo Forlanini, 00152 Roma, Italy.
Michele Massimo GuliziaU.O.C. Cardiologia, Ospedale Garibaldi-Nesima, Azienda di Rilievo Nazionale e Alta Specializzazione "Garibaldi", 95122 Catania, Italy.
Fabrizio OlivaDe Gasperis Cardio Center, Niguarda Hospital, 20162 Milano, Italy.
Furio ColivicchiEmergency Department, Clinical and Rehabilitation Cardiology Unit, San Filippo Neri Hospital, ASL Roma 1, 00135 Rome, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Therapeutic approaches based on gene silencing technologies represent a new opportunity to manage hypercholesterolemia. Inclisiran is a small interfering RNA that targets proprotein convertase subtilisin/kexin type 9 (PCSK9) mRNA. Clinical studies have demonstrated that inclisiran is effective, safe, and well-tolerated in reducing low-density lipoprotein cholesterol (LDL-C) in patients with familial hypercholesterolemia, atherosclerotic cardiovascular disease, and atherosclerotic cardiovascular disease risk equivalents. A meta-analysis of phase 3 trials demonstrated a 51% reduction in LDL-C levels at 18 months as compared with placebo. Adverse event incidence was found to be comparable in individuals treated with inclisiran and those receiving placebo, though the reactions at the site of injection were more common in patients receiving inclisiran as compared with those receiving placebo. The recommended inclisiran dose is 284 mg administered as a subcutaneous injection to be repeated after three months with a subsequent 6-month maintenance regimen. Overall, since the pharmacological efficacy of inclisiran in LDL-C reduction is comparable to that of monoclonal antibodies against PCSK9, the longer effect duration and the favorable safety profile may favor this newer approach for hypercholesterolemia management.

Indexed as

cardiovascular diseasehypercholesterolemiainclisiranLDL-cholesterolsiRNA

Identifiers

PMID39076203
PMCPMC11269059

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.